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Abstract
Objective—To determine the prevalence
and clinical significance of hepatitis G
virus (HGV) infection in a large cohort of
patients with primary Sjögren’s syndrome
(SS).
Patients and methods—The study in-
cluded 100 consecutive patients (92 female
and eight male), with a mean age of 62
years (range 31–80) that were prospec-
tively visited in our unit. All patients
fulfilled the European Community crite-
ria for SS and underwent a complete
history, physical examination, as well as
biochemical and immunological evalua-
tion for liver disease. Two hundred volun-
teer blood donors were also studied. The
presence of HGV-RNA was investigated in
the serum of all patients and donors. Adi-
tionally, HBsAg and antibodies to hepati-
tis C virus were determined.
Results—Four patients (4%) and six vol-
unteer blood donors (3%) presented HGV-
RNA sequences in serum. HGV infection
was associated with biochemical signs of
liver involvement in two (50%) patients.
When compared with primary SS patients
without HGV infection, no significant dif-
ferences were found in terms of clinical or
immunological features. HCV coinfection
occurs in one (25%) of the four patients
with HGV infection.
Conclusion—The prevalence of HGV in-
fection in patients with primary SS is low
in the geographical area of the study and
HCV coinfection is very uncommon. HGV
infection alone does not seen to be an
important cause of chronic liver injury in
the patients with primary SS in this area.
(Ann Rheum Dis 1998;57:42–44)
Sjögren’s syndrome (SS) is a systemic auto-
immune disease that mainly aVects exocrine
glands and that usually presents as a persistent
dryness of the mouth and the eyes because of
functional impairment of the salivary and
lacrimal glands. The histological hallmark is a
focal lymphocytic infiltration of the exocrine
glands. In the absence of an associated connec-
tive tissue disease, patients with this condition
are classified as having primary SS. The factors
that might trigger this autoimmune disorder
remain unknown, but viral infections have
repeatedly been suggested as a possible cause.1
Furthermore, a possible relation between
hepatitis C virus (HCV), a member of the Fla-
viviridae family, which is a virus that can be
excreted in saliva, and SS has recently been
postulated.2 Using polymerase chain reaction
(PCR) assay, some studies3 4 showed a preva-
lence of HCV infection in primary SS signifi-
cantly high when compared with the preva-
lence of HCV infection that has been found in
general population and raises the possibility of
a link between HCV infection and SS.
The hepatitis G virus (HGV) is a recently
discovered member of the Flaviviridae family
that may cause acute and chronic infection in
humans.5 HGV is similar in sequence to the
hepatitis GB-C (HGBV-C) virus that may be
responsible of cases of non-A, non-B hepatitis.6
HGV and HGBV-C are probably diVerent iso-
lates of the same agent.7 Preliminary data indi-
cate that HGV/HGBV-C infection can be
detected in a comparatively high proportion of
apparently healthy volunteer blood donors, in
recipients of blood transfusions, patients on
haemodialysis, intravenous drug abusers, and
in patients with acute and chronic liver
disease.5 6 8–11 Although it may occur in 3% to
8% of patients with cryptogenic disease5 8 9
HGV sequences are also found in 10% to
nearly 20% of chronic liver disease patients
who are infected by the hepatitis B virus (HBV)
or by the hepatitis C virus (HCV).5 8 9
To the best of our knowledge, there have
been no previous studies about the implication
of HGV infection in extrahepatic syndromes
associated with HCV infection, such as cry-
oglobulinaemia, glomerulonephritis or SS. To
determine if there is a possible link between SS
and HGV infection, and the possible relation
with other hepatitis virus infections, we have
investigated the presence of HGV-RNA se-
quences in a large series of patients with
primary SS as well as their clinical significance.
Methods
We included 100 consecutive patients (92
female and eight male; mean age 62 years;
range 31–80) who attended our Systemic
Autoimmune Diseases Unit from March 1993
until August 1996. All patients were white and
fulfilled four or more of the diagnostic criteria
for SS proposed by the European Community
Study Group in 1993.12 None of these patients
presented clinical or immunological evidence
of other systemic autoimmune disease and no
patient had been previously diagnosed as
having primary biliary cirrhosis or auto-
immune hepatitis.
Two hundred consecutive, first donation,
volunteer blood donors were also studied. One
hundred and fourteen were men and 86
women. Their mean age was 39 years, ranging
from 18 to 65.
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For HGV-RNA analysis, RNA was extracted
from 140 µl of serum using silica gel based
membrane columns (QIAamp HCV, Qiagen,
Hilden, Germany) and eluted in a final volume
of 50 µl of Rnase free water. Complementary
DNA was synthesised from 10 µl of RNA by 45
minutes incubation at 42°C with 25 U of
Expand reverse transcriptase (Boehringer
Mannheim, Mannheim, Germany), 50 nM of
random primers, 1 U of ribonuclease inhibitor,
and 200 µM of each deoxynucleotide in a final
volume of 20 µl. Specific amplification of the
5'non-translated region (5'NCR) of HGV
genome was carried out using the following
primers: 5'-CGG CCA AAA GGTGGTGGA
TG-3', sense primer, position 101–120 and
5'-CGA CGA GCC TGA CGT CGG G-3'
antisense primer, position 285–267 (Hepatitis
G virus Primer and Capture Probe Set,
Boehringer Mannheim, Mannheim, Germain)
and digoxigenin labelled deoxynucleotides
(PCR ELISA DIG labelling, Boehringer Man-
nheim,Mannheim, Germany) according to the
instructions of the manufacturer. PCR was
performed in a Techne Progene thermal cycler
(Techne, Cambridge, UK) by 40 cycles of
94°C for 45 seconds, 55°C for one minute, 72°
C for one minute, and a final extension cycle of
five minutes at 72°C. Digoxigenin labelled
PCR products were detected by solution
hybridisation to a biotin labelled 5'NCR
specific capture probe that is complementary
to the inner part of the amplicon. Hybrids were
immobilised to a streptavidin coated microtitre
plate surface. The bound hybrid was detected
by an anti-digoxigenin peroxidase conjugate
(PCR ELISA DIG detection, Boehringer
Mannheim, Mannheim, Germany). Appropi-
ate positive and negative controls were used for
extraction, retrotranscription, amplification,
and detection steps. Positive controls included
serum samples known to contain HGV RNA in
high and low concentration, and amplification
and detection of a control human gene (tissue
plasminogen activator gene). Negative controls
included serum samples negative for HGV
RNA, as well as reagents without template.
Absorbance was measured at 405 nm. The
mean optical density (OD) was 0.046 (range:
0.038–0.057) in negative controls and 1.204
(range 1.021–1.427) in positive controls. Sam-
ples giving a signal five times above the mean
OD of negative controls were considered posi-
tive. Positive results were accepted upon agree-
ment on repeated testing.
Serum samples from all patients were tested
for hepatitis B surface antigen (HBsAg) by
ELISA. Serum from all patients were analysed
for HCV antibodies by a third generation
ELISA (Ortho 3.0 Diagnostic Systems, Neck-
argemund, Germany). In anti-HCV positive
serum samples, presence of HCV-RNA was
analysed by PCR (Promega, Madison, WI,
USA).
STATISTICAL ANALYSIS
For analysing qualitative diVerences we used a
÷2 test or the Fisher’s exact test when appropri-
ate. For comparison of quantitative para-
meters, Student’s test was used in large
samples of similar variance, and non-
parametric Mann-Whitney U test for small
samples. p Values < 0.05 were considered to
indicate statistical significance and odds ratio
(OR) were calculated with 95% confidence
intervals (CI).
Results
HGV-RNA was detected in four (4%) patients
with primary SS and in six (3%) of the volun-
teer blood donors studied (the diVerence was
not statistically significant). All patients were
women. Mean age at the onset of clinical
manifestations of dry syndrome was 40 years
(range 29–48) and at the time of protocol was
49 years (range 31–69). When primary SS
patients with and without HGV infection were
compared, no significant diVerences were
found (table 1).
One patient showed HCV-HGV coinfection,
and presented hepatomegaly and increased
serum aspartate transaminase (AST) and
serum alanine transaminase (ALT). Another
patient, with HGV infection alone, had an
intermittent four year history of mildly raised
transaminase serum activities without evidence
of other causes of hepatic involvement. No
clinical signs of liver disease were present in
this patient. In the two remaining HGV
positive patients, no clinical or biochemical
evidence of liver involvement was found.
Antibodies to HCV were present in 14
(14%) patients with primary SS and in two
(1%) of the blood donors studied (p < 0.001,
OR 16.1, CI 3.4, 105.0). HCV-RNA was posi-
tive in all of them. HBsAg was detected in two
(2%) patients with primary SS, both with HCV
coinfection and liver involvement, whereas
HBsAg was detected in only one (0.5%) of the
control group.
Discussion
In this study, we analysed the frequency and
consequences of HGV infection in patients
with primary SS. HGV-RNA sequences were
found in only 4% of patients with primary SS,
similar to the prevalence found in the healthy
volunteer blood donors studied (3%). In
contrast, HCV infection was detected in 14%
of patients with primary SS, whereas the
proportion in the blood donors was only 1%.
Table 1 Clinical and immunological manifestations of patients with primary SS (SS)
and HGV infection compared with patients without HGV infection
SS with HGV infection
(n=4) (%)
SS without HGV infection
(n=96) (%) p Value
Dry mouth 3 (75) 95 (99) NS
Dry eyes 3 (75) 92 (96) NS
Parotidomegaly 3 (75) 34 (35) NS
Esplenomegaly 1 (25) 7 (7) NS
Articular involvement 2 (50) 44 (46) NS
Raynaud’s phenomenon 0 (0) 14 (15) NS
Cutaneous vasculitis 0 (0) 13 (14) NS
Pulmonary involvement 2 (50) 10 (10) NS
Liver involvement 2 (50) 13 (14) NS
Peripheral neuropathy 0 (0) 11 (11) NS
Autoimmune thyroiditis 0 (0) 16 (17) NS
ANA (+) 3 (75) 63 (66) NS
RF (+) 2 (50) 42 (44) NS
Ro-SSA (+) 1 (25) 25 (26) NS
La-SSB (+) 0 (0) 15 (16) NS
ANA=antinuclear antibodies. RF= rheumatoid factor. NS=not significant diVerence.
HGV infection in Sjögren’s syndrome 43
 group.bmj.com on July 25, 2011 - Published by ard.bmj.comDownloaded from 
The clinical consequences of chronic HGV
infection have not yet been clearly defined.
HGV related disease is generally mild, with
normal levels of aminotransferases. Clinical
data show that many people infected with
HGV alone do not show evidence of liver
disease. In fact, abnormal ALT serum activities
in subjects with HGV infection can often be
adscribed to a coexisting infection with HCV
or HBV.5 9 Virtually all increases of ALT in
patients on maintenance haemodialysis in-
fected by HGBV-C were ascribable to coinfec-
tion with HCV or HBV.13
Three clinical outcomes have been described
for the HGV infection14: rapid recovery with
resolution of raised transaminase activity and
eventual clearance of viraemia, delayed recov-
ery with intermittent increased transaminases,
and chronic hepatitis.6 Certainly, there are no
prospective studies that report histologically
the progression from acute HGV/HGBV-C
infection through various stages of chronic
hepatitis tothedevelopmentofcirrhosis,hepato-
cellular carcinoma, or end stage liver disease.
In our patients with primary SS, HGV infec-
tion was associated with biochemical signs of
liver involvement in two of four patients, but in
one of these, HCV infection was also detected.
In this patient with HCV-HGV dual infection
transaminase activities were higher than in the
patient with HGV infection alone. Thus, HGV
infection alone does not seem to be an impor-
tant cause of chronic liver injury in our patients
with primary SS, and is associated with a quite
small increase in aminotransferases in only one
(1%) of our patients with primary SS.
In conclusion, HGV seems to play a small
part in the aetiology of liver involvement
among patients with primary SS, but HGV-
RNA detection is recommended for patients
with primary SS and unexplained liver disease,
especially in those patients without evidence of
HBV or HCV infections.
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